Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mars
Christchurch, Canterbury, New Zealandmarsbioimaging.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
MARS Bioimaging has developed the world’s first commercial pre-clinical spectral CT scanner using Medipix3RX detectors. Their technology enables high-resolution molecular imaging with applications in cancer detection and development of new contrast agents. The company is preparing to launch a human extremity scanner for clinical use pending regulatory approvals.
- Therapeutic areas
- OncologyOther
- Modalities
- Device
- Industry
- Medical Imaging
02
Partnerships
CERN (Medipix collaboration)University of CanterburyUniversity of Otago
Beyond the preview
Go deeper on Mars.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mars.